Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Zhang, Xiaopeng; Pan, Chunchen; Zhou, Lei; Cai, Zhaogen; Zhao, Shufang; Yu, Donghong
• Is Part Of: BMC cancer. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 12
• Publication Date: 2016-12
• Subjects: α-2, 6-sialic acid transferase -- DDP -- HeLa -- Apoptosis -- Invasion; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-016-2981-y
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. However, the effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells. Methods Knockdown of ST6Gal-I was performed by shRNA and HeLa cells combination with cisplatin were tested. Results We showed that down-regulation of ST6Gal-I promoted cell apoptosis and inhibited proliferation and invasion in cervical cancer cells. Knockdown of ST6Gal-I by RNA interference increased the sensitivity of HeLa cells to cisplatin in vitro, and reduced tumor volume and suppressed subcutaneous tumor growth in response to cisplatin treatment in a xenograft mouse model in vivo. Conclusions The results provide new information that ST6Gal-I plays an important role in several biological or pathological processes including drug resistance in cervical cancer and may be a potential therapeutic target to improve the response to chemotherapy in cervical cancer patients.